Skip to main content

Advertisement

Table 1 Baseline demographics and clinical characteristics of the pooled cohorts from 8 trials of linagliptin versus total comparators (placebo and active treatment)

From: Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

  Linagliptin (n= 3319) Total comparators (n= 1920)
Gender, % of patients   
   Male/female 53.7/46.3 58.6/41.4
Age, years 58 ± 10 58 ± 10
BMI, kg/m2 28.8 ± 5.0 29.1 ± 4.9
Race, % of patients   
   White 59.7 61.8
   Black 1.4 1.6
   Asian 38.9 36.6
HbA1c, mmol/mol 65 ± 10 64 ± 10
HbA1c, % 8.1 ± 0.9 8.0 ± 0.9
FPG, mmol/L 9.3 ± 2.4 9.4 ± 2.3
Diabetes duration (known), % of patients
   ≤ 1 years 12.1 12.2
   1-5 years 34.8 36.6
   > 5 years 53.1 51.2
Previous oral glucose-lowering agents, % of patients
   None 17.3 17.3
   1 42.8 49.9
   2 39.7 32.5
   ≥ 3 0.2 0.2
CV risk factors, % of patients
   Metabolic syndrome* 60.3 61.7
   Coronary artery disease 10.4 11.0
   Cerebrovascular disease 2.9 3.9
   Peripheral artery disease 2.3 3.0
   Hypertension 63.8 66.0
   Ex-/current smoker 22.9/14.4 24.2/15.9
eGFR using CG/MDRD formulae, % of patients
   Normal 74.9/55.4 77.3/55.4
   Mildly impaired 19.9/37.3 18.5/38.1
   Moderately impaired 2.2/4.3 1.9/4.3
   Severely impaired 0.1/0.1 0.1/0.1
CV medication, % of patients
   Acetyl-salicylic acid 29.5 30.5
   Antihypertensive 60.0 63.0
   Lipid-lowering therapy 39.5 42.1
   Any of the above 72.8 75.5
Framingham 10-year CV risk score
   Score, % 9.8 ± 8.2 10.3 ± 8.4
   Score > 15%, % of patients 27.8 31.1
  1. *International Diabetes Federation definition. Values are mean ± SD, unless otherwise stated. BMI, body mass index; CG, Cockcroft-Gault; CV, cardiovascular; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; MDRD, Modification of Diet in Renal Disease study.